A Phase IB/II Study of AMG 420 in Patients with Recurrent or Persistent Multiple Myeloma

Full Title

A Phase 1b/2 Multicenter, Open-label, Expansion Study to Assess the Safety and Efficacy of AMG 420 as Monotherapy in Subjects With Relapsed and/or Refractory Multiple Myeloma

Purpose

The purpose of this study is to find the highest dose of the investigational drug AMG 420 that can be given in patients with multiple myeloma that has come back or continued to grow despite treatment. AMG 420 is a bispecific antibody, meaning it can attach to two different proteins: one on the surface of cancer cells, and the other on the surface of cells in the immune system called T cells. Researchers think AMG 420 may increase the immune system’s ability to fight cancer by activating T cells to target and kill multiple myeloma cells. AMG 420 is given intravenously (by vein).

Eligibility

To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Patients must have multiple myeloma that came back or continues to grow despite at least three prior regimens of treatment.
  • Patients should recover from the serious side effects of previous therapies before entering the study.
  • Patients must be able to walk and do routine activities for more than half of their normal waking hours.
  • This study is for patients age 18 and older.

For more information about this study and to inquire about eligibility, please contact Dr. Alexander Lesokhin at 212-639-3069.

Protocol

19-212

Phase

I/II

Disease Status

Relapsed or Refractory

Investigator

Co-Investigators